TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

81 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Eczema / atopic dermatitis

    Molecular Signatures of Cutaneous Dupilumab Response

    Studying how dupilumab affects immune cells in eczema skin

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • COPD (chronic lung disease)

    Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

    Testing how a genetic change in alpha-1 antitrypsin affects immune and lung responses to a pneumonia

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.

    ✓ Study care freePhase 4Ages 19+Learn more →
  • COPD (chronic lung disease)

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +39 more US sites · Get directions →

    This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • COPD (chronic lung disease)

    A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

    Testing the long-term safety of astegolimab in people with COPD

    📍 UAB Lung Health Center · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

    ✓ Study care freePhase 3Ages 40–90Learn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • COPD (chronic lung disease)

    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

    Testing whether tezepelumab is safe and works for adults with COPD

    📍 Research Site · Foley, AL · +39 more US sites · Get directions →

    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Lupus (SLE)Eczema / atopic dermatitis

    Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

    Testing whether baricitinib is safe in people with Job syndrome and lupus or eczema

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections and problems with blood vessels, connective tissues, and bones.

    ✓ Study care freePhase 1Ages 12–120Learn more →
  • Type 2 diabetesHigh blood pressure

    Polypill for Prevention of Cardiomyopathy

    Testing a pill combination to prevent heart muscle disease in people with type 2 diabetes and high

    📍 UT Southwestern Medical Center · Dallas, TX · Get directions →

    This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily.

    ✓ Study care freePhase 1Ages 18–100Learn more →
  • High blood pressure

    Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

    Testing a device used through a blood-vessel procedure for type 2 diabetes and high blood pressure

    💵 May compensate

    📍 Hospital Paitilla Clinicas y Hospitales · Panama City, · Get directions →

    This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.

    ✓ Study care freePhase 1Ages 21–65Learn more →
  • Obesity / overweightHigh blood pressure

    A Study of LY3971297 in Healthy Participants

    Testing side effects and how the body processes an injection in healthy and obese people with high

    📍 CenExel ACT · Anaheim, CA · +2 more US sites · Get directions →

    The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • COPD (chronic lung disease)Asthma

    The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

    Testing whether positive airway pressure helps a lung medicine (NAC) reach mucus plugs in asthma or

    📍 UCSF Airway Clinical Research Center · San Francisco, CA · Get directions →

    The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.

    ✓ Study care freePhase 4Ages 18–85Learn more →
  • COPD (chronic lung disease)

    📍 GSK Investigational Site · Sheffield, AL · +39 more US sites · Get directions →

    Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Eczema / atopic dermatitis

    A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

    Testing whether a medicine called abrocitinib helps children with eczema and is safe

    📍 Cahaba Dermatology & Skin Health Center, LLC · Birmingham, AL · +9 more US sites · Get directions →

    This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks.

    ✓ Study care freePhase 3Ages 6–11Learn more →
  • Eczema / atopic dermatitis

    A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

    Testing BBT001 in healthy adults and adults with eczema

    📍 First OC Dermatology · Irvine, CA · +2 more US sites · Get directions →

    This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

    ✓ Study care freePhase 1Ages 18–72Learn more →
  • Eczema / atopic dermatitis

    Dupilumab De-escalation in Pediatric Atopic Dermatitis

    Testing whether stopping or lowering eczema treatment works for kids

    📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →

    This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

    ✓ Study care freePhase 4Ages 1–17Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

    Testing a new drug dose in people with eczema and healthy volunteers

    📍 Clinical Site 101 · Fair Lawn, NJ · Get directions →

    This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

    Testing a drug taken with empagliflozin in adults with type 2 diabetes and heart disease

    📍 Pinnacle Research Group, LLC · Anniston, AL · +39 more US sites · Get directions →

    This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • COPD (chronic lung disease)

    Multi-Center Clean Air Randomized Controlled Trial in COPD

    Testing whether using an air cleaner improves COPD symptoms and quality of life

    📍 University of Alabama, Lung Health Center · Birmingham, AL · +10 more US sites · Get directions →

    This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.

    ✓ Study care freePhase 3Ages 40+Learn more →
  • COPD (chronic lung disease)

    📍 Chandler Clinical Research Trials- Site Number : 8400025 · Chandler, AZ · +39 more US sites · Get directions →

    This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Lebrikizumab in Moderate-to-severe Atopic Dermatitis

    Testing a medicine called lebrikizumab for long-term improvement in eczema

    📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →

    This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightHigh blood pressure

    Mitigating the Pro-inflammatory Phenotype of Obesity

    Testing whether 4 weeks of a blood pressure medicine can reduce inflammation in people with obesity

    📍 University of Kansas Medical Center · Kansas City, KS · Get directions →

    The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.

    ✓ Study care freePhase 1Ages 18–79Learn more →
  • Eczema / atopic dermatitis

    📍 Applied Research Center Of Arkansas /ID# 268547 · Little Rock, AR · +29 more US sites · Get directions →

    Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment.

    ✓ Study care freePhase 3Ages 2–11Learn more →
  • High blood pressure

    📍 Sarfez Pharmaceuticals, Inc. · Vienna, VA · Get directions →

    A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • COPD (chronic lung disease)

    📍 Equity Medical Bowling Green · Bowling Green, KY · +2 more US sites · Get directions →

    Randomized study of single and multiple doses of BBT002 in healthy volunteers and in adult patients with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP).

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • COPD (chronic lung disease)

    Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

    Testing an add-on medicine to treat moderate to severe COPD with type 2 inflammation

    📍 GSK Investigational Site · Loxahatchee Groves, FL · +3 more US sites · Get directions →

    Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Eczema / atopic dermatitis

    The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

    Testing how Botox changes skin immune signals in people with eczema

    📍 University of Pittsburgh Medical Center · Pittsburgh, PA · +1 more US site · Get directions →

    The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Ethnic Differences in Mechanisms of Action of Dupilumab

    Studying how a common eczema treatment works differently by race

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Eczema / atopic dermatitis

    A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

    Testing safety and effectiveness of a 1% eczema cream in babies and toddlers

    📍 AllerVie Clinical Research · Birmingham, AL · +36 more US sites · Get directions →

    The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

    ✓ Study care freePhase 3Learn more →
  • Eczema / atopic dermatitis

    Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

    Testing the safety of LPX-TI641 and how the body handles it in eczema

    📍 Red River Research Partners · Fargo, ND · +1 more US site · Get directions →

    The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • COPD (chronic lung disease)

    A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

    Comparing inhalers to see how triple breathing medicine affects heart and lung outcomes in COPD

    📍 Research Site · Athens, AL · +39 more US sites · Get directions →

    This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Prevention of Progression of Prediabetes, Obesity and CV Risk

    Testing ways to stop prediabetes and obesity from getting worse

    💵 May compensate

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Eczema / atopic dermatitis

    FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

    Testing the safety of PF-07832837 in healthy people and eczema patients

    📍 Anaheim Clinical Trials, LLC · Anaheim, CA · +2 more US sites · Get directions →

    The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Eczema / atopic dermatitis

    A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

    Testing how a new medicine works and is tolerated in people with eczema

    📍 Sitryx Clinical Site · Arkansas City, AR · +5 more US sites · Get directions →

    The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD). The objectives of this study are to determine the safety, tolerability and levels of SYX-5219 in the blood and urine when SYX-5219 is given in each part of the study (SAD, MAD, Food Effect and Participants with AD).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • COPD (chronic lung disease)

    Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

    Comparing inhaled triple versus double medicines for COPD lung airways after wood smoke exposure

    💵 May compensate

    📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →

    This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.

    ✓ Study care freePhase 4Ages 35–85WomenLearn more →
  • COPD (chronic lung disease)

    Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

    Comparing nebulizer and inhaler treatments for COPD symptoms

    📍 The University of Tennessee Graduate School of Medicine · Knoxville, TN · Get directions →

    The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity

    📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    ✓ Study care freePhase 3Ages 45–99Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people

    💵 May compensate

    📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).

    ✓ Study care freePhase 3Ages 18–99Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    Testing how well NNC0487-0111 works versus placebo in heart failure with excess body weight

    📍 Advanced Cardiovascular, LLC · Alexander City, AL · +39 more US sites · Get directions →

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweightHigh blood pressure

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Testing treatments to lower high pressure in liver veins in people with advanced liver disease and

    💵 May compensate

    📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • COPD (chronic lung disease)

    A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

    Testing how a study medicine affects safety and symptoms in people with COPD

    📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.

    ✓ Study care freePhase 2Ages 35–80Learn more →
  • COPD (chronic lung disease)

    A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

    Testing the safety and effects of an inhaled medicine for COPD

    📍 University of Alabama at Birmingham · Birmingham, AL · +6 more US sites · Get directions →

    This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Obesity / overweightHigh blood pressureCOPD (chronic lung disease)

    Feasibility of Semaglutide in Advanced Lung Disease

    Testing whether semaglutide can be given safely to people with advanced lung disease

    📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →

    The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Eczema / atopic dermatitis

    📍 Leo Pharma Investigational site · Birmingham, AL · +14 more US sites · Get directions →

    The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life.

    ✓ Study care freePhase 3Ages 1–11Learn more →
  • Eczema / atopic dermatitis

    Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

    Testing an approach involving the skin microbiome to treat eczema

    📍 University of California, San Diego: Dermatology Clinical Trials Unit · San Diego, CA · +7 more US sites · Get directions →

    This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S.

    ✓ Study care freePhase 1Ages 6+Learn more →
  • Eczema / atopic dermatitis

    A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

    Testing an anti-inflammatory medicine in adults with eczema who did not respond enough to dupilumab

    📍 Cahaba Dermatology & Skin Health Center /ID# 263855 · Birmingham, AL · +39 more US sites · Get directions →

    Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment.

    ✓ Study care freePhase 3Ages 18–63Learn more →
  • Eczema / atopic dermatitis

    A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

    Testing a new treatment for moderate to severe eczema in people 12+ years old

    📍 Nektar Investigative Site · St. Petersburg, FL · Get directions →

    This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.

    ✓ Study care freePhase 3Ages 12+Learn more →
  • Heart / cardiovascular disease

    COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

    Testing colchicine and plain aspirin, alone or together, for heart outcomes in high-risk type 2

    📍 Curtin University · Bentley, Western Australia · Get directions →

    To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.

    ✓ Study care freePhase 3Ages 55–80Learn more →
  • Type 2 diabetesHeart / cardiovascular disease

    FES Cycling With BFR in the Spinal Cord Injury Population

    Testing a cycling exercise program with added arm-leg pressure for people with spinal cord injury

    📍 Lyndhurst Centre · Toronto, Ontario · Get directions →

    Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury/disease (SCI/D) population. Many SCI/D patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • COPD (chronic lung disease)

    eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

    Testing an add-on medicine started early to treat COPD with type 2 inflammation

    📍 GSK Investigational Site · Doral, FL · Get directions →

    Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

    ✓ Study care freePhase 3Ages 40–75Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    Testing how semaglutide works in people with heart failure and obesity

    📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.

    ✓ Study care freePhase 1Ages 20–80Learn more →
  • Obesity / overweightHigh blood pressure

    Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study

    Testing how an egg-derived peptide affects health in people with obesity and high blood pressure

    📍 University of Alberta · Edmonton, Alberta · Get directions →

    Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides.

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

    Testing a medicine to see its cardiovascular effects in adults on dialysis

    📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →

    This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Fairhope, AL · +39 more US sites · Get directions →

    International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Obesity / overweightHigh blood pressure

    Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

    Studying what happens to heart health and weight after stopping a weight-loss drug in people with

    📍 Leadership Sinai Centre for Diabetes · Toronto, Ontario · Get directions →

    Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Obesity / overweightType 2 diabetesHeart / cardiovascular disease

    Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

    Testing the diabetes medicine pioglitazone in people with type 2 diabetes, obesity, and heart

    📍 Texas Diabetes Institute/UH · San Antonio, TX · Get directions →

    Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.

    ✓ Study care freePhase 4Ages 30–70Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure

    Metabolic Effects of Angiotensin-(1-7)

    Testing how angiotensin-(1-7) affects body metabolism in obesity

    📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →

    The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Heart / cardiovascular diseaseHigh blood pressureCOPD (chronic lung disease)

    : Vascular Function in Health and Disease

    Studying how blood vessel function works in health and diseases like heart problems, high blood

    📍 George E Wahlen VA Medical Center · Salt Lake City, UT · Get directions →

    Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively sets the level of vascular tone.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Showing the first 60 of 81. Add filters or a location to narrow down.